Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells

Cancer Research

Volumn 62, Issue 5, 2002, Pages 1471-1476

  Ota, Seisuke ^a   Ono, Toshiro ^a   Morita, Akimichi ^b   Uenaka, Akiko ^a   Harada, Mine ^a   Nakayama, Eiichi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BREFELDIN A; CHLOROQUINE; CYCLOHEXIMIDE; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEINASE INHIBITOR; TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; MALE; MASTOCYTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; BREFELDIN A; CHLOROQUINE; CYCLOHEXIMIDE; EPITOPES, T-LYMPHOCYTE; FEMALE; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036494627     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Tumor antigens recognized by T lymphocytes
2. Murine tumor antigens: Is it worth the search?
3. Tumor antigens
4. T cell defined tumor antigens
5. A new era for cancer immunotherapy based on the genes that encode cancer antigens
6. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
7. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts
8. Mutated mitogen-activated protein kinase: A tumor rejection antigen of mouse sarcoma
9. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia
10. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
11. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
12. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
13. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
14. +T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo
15. +T cell response: Lessons from the EBV nuclear antigen EBNA 1
16. Advances in vaccine adjuvants
17. Cell-free tumor antigen peptide-based cancer vaccines
18. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
19. Interleukin-12 as an adjuvant for cancer immunotherapy
20. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
21. Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system
22. A novel method for producing antipeptide antibodies. Production of site-specific antibodies to the T cell antigen receptor β-chain
23. Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine
24. Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide
25. Identification of a unique antigen peptide pRL1 on BALB/c RL♂ 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene
26. Definition of a unique cell surface antigen of mouse leukemia RL♂ 1 by cell-mediated cytotoxicity
27. A transplantable mast-cell neoplasm in the mouse
28. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells
29. b
30. Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes
31. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
32. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
33. The effect of protease inhibitors, leupeptin and E64d, on differentiation of C2C12 myoblasts in tissue culture
34. Diversity of epitopes recognized by cytotoxic T lymphocytes that are specific for rejection antigen peptide pRL1a presented on BALB/c leukemia RL♂ 1
35. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
36. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages
37. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages
38. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules
39. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis
40. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells
41. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class 1 presentation pathway
42. Introduction of soluble protein into the class I pathway of antigen processing and presentation
43. The efficiency of antigen delivery from macrophage phagosomes into cytoplasm for MHC class I-restricted antigen presentation
44. CTL epitope generation is tightly linked to cellular proteolysis of a Listeria monocytogenes antigen
45. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: Involvement of nonproteasomal cytosolic proteases in antigen processing?
46. Proteasomes can either generate or destroy MHC class I epitopes: Evidence for nonproteasomal epitope generation in the cytosol
47. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides
48. MHC class I molecules can direct proteolytic cleavage of antigenic precursors in the endplasmic reticulum